Melbourne – October 21, 2026 -- Telix Manufacturing Solutions (TMS) runs seven facility groups across North America, Europe and Asia Pacific, anchored by 29 accredited radiopharmacies in the United States, to deliver radiopharmaceutical doses to patients before the products decay. The short half-life of these products makes efficient manufacturing and logistics a prerequisite for timely delivery.
RLS network delivers patient doses from 29 U.S. sites
The RLS Radiopharmacies network is accredited by The Joint Commission. Each site is staffed by Nuclear Pharmacists, Radiation Safety Officers and a dedicated courier fleet.
Seneffe and Yokohama anchor commercial supply in Europe and Asia Pacific
TMS Seneffe, in Belgium's RadioPharma Valley, is one of the largest GMP production facilities of its kind in Europe and Telix's primary manufacturing site for the region. It includes a dedicated laboratory for alpha therapies.
TMS Yokohama is Telix's first cyclotron facility in Asia Pacific. It supplies commercial and clinical drug product and also handles research and development.
ARTMS in Vancouver produces isotopes through decentralized cyclotrons
ARTMS specializes in decentralized, large-scale cyclotron production of medical isotopes for Telix's commercial products. Its QUANTM Irradiation System (QIS) is built for higher-yield production of commercially important isotopes.
Melbourne, Houston and Los Angeles sites feed the development pipeline
TMS North Melbourne handles early-stage R&D and radiopharmaceutical production in the Parkville Precinct, close to major hospitals and research centres. IsoTherapeutics, just outside Houston, Texas, covers radiochemistry, bioconjugation and isotope processing.
Telix Targeting Technologies (T3) in Los Angeles offers end-to-end preclinical capabilities, from antibody screening to in-vivo studies. It also runs a novel biologics platform for the next generation of Telix precision medicines.